What is Selank as a chemical entity, and why does characterisation matter?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) structurally related to the immunomodulatory tetrapeptide tuftsin, with additional residues that alter its physicochemical profile and stability relative to the parent fragment. From an analytical standpoint, the relevant facts are its amino-acid sequence, theoretical monoisotopic and average molecular weights, and the presence of multiple proline and basic (lysine, arginine) residues that influence chromatographic retention and ionisation behaviour. Because it is manufactured by solid-phase peptide synthesis, every batch carries a characteristic profile of synthesis-related impurities — deletion sequences, incomplete deprotection products and counterion residues — that must be quantified rather than assumed. Selank has been referenced in the clinical research literature as a peptide anxiolytic candidate, for example in studies of generalised anxiety disorder response patterns, which is why it appears in research procurement searches. However, the existence of such studies says nothing about the identity or quality of any particular vial of material. For an Australian research laboratory, characterisation matters because two batches labelled 'Selank' can differ substantially in net peptide content, related-substance profile and residual solvent load. Robust characterisation converts a label into verifiable data: a confirmed sequence, a measured purity value against defined acceptance criteria, and a stability position appropriate to the storage regime. This section establishes the terminology used throughout — identity, purity, related substances, net peptide content and stability — each of which corresponds to a specific analytical test discussed below. No statement here should be read as describing a physiological effect; the focus is entirely on the molecule as a characterised research reagent.
How is Selank identity confirmed by mass spectrometry?
Identity confirmation answers a single question: is the molecule in the vial the intended heptapeptide? The primary tool is electrospray ionisation mass spectrometry (ESI-MS), which measures the mass-to-charge ratio of the intact peptide. Because Selank carries multiple basic residues, it readily forms multiply charged ions such as [M+2H]2+ and [M+3H]3+; deconvolution of these charge states yields the observed molecular mass, which is compared against the theoretical value calculated from the sequence. An acceptable match — typically within a few parts per million on a high-resolution instrument, or within the calibrated tolerance of a lower-resolution system — supports identity but does not by itself prove sequence. To confirm the actual order of residues, tandem mass spectrometry (MS/MS) is used: the precursor ion is fragmented to generate b- and y-ion series, and the observed fragment masses are mapped against the predicted fragmentation of Thr-Lys-Pro-Arg-Pro-Gly-Pro. Proline-rich sequences produce characteristic fragmentation behaviour, which analysts account for during interpretation. A complete identity package therefore comprises an intact-mass measurement plus fragment-ion sequence mapping, and both should appear on the analytical report. For a research buyer, the practical checkpoints are: an annotated mass spectrum showing the expected charge envelope, a stated theoretical versus observed mass, and — for full assurance — an MS/MS sequence confirmation. Where only a single-point mass is provided, identity is supported but sequence integrity is unverified. This distinction is important when selecting between comparable products. Identity testing is a chemistry exercise; it establishes what the material is, not what it does.
How is Selank purity measured and what acceptance criteria apply?
Purity for a synthetic peptide is most commonly reported as chromatographic purity by reversed-phase high-performance liquid chromatography (RP-HPLC), expressed as the percentage of total integrated peak area attributable to the main peak. A typical method uses a C18 column, a water/acetonitrile gradient with an acidic modifier such as trifluoroacetic acid, and UV detection near 214 nm where the peptide bond absorbs. For Selank, method development must achieve baseline separation of the main peak from closely eluting related substances such as deletion or truncation sequences. Acceptance criteria are defined per specification — many research materials are documented at ≥95% or ≥98% area purity — and the report should state the criterion applied, not merely the result. A single main peak, however, can mask co-eluting impurities, which is why peak-purity assessment (for example using photodiode-array spectral homogeneity across the peak, or orthogonal LC-MS) adds confidence that the reported peak represents one compound. Related-substance or impurity profiling extends this by identifying and quantifying individual impurities against reporting, identification and qualification thresholds. Complementary tests give a fuller purity picture: net peptide content (accounting for water and counterion mass) reflects how much actual peptide is present; residual TFA counterion analysis quantifies the acid associated with the basic residues; and Karl Fischer titration measures water content. Together these prevent a high area-purity figure from being misread as a high mass fraction of peptide. An Australian laboratory evaluating material should look for the HPLC method summary, the chromatogram, the stated acceptance criterion and supporting content data — all framed as quality metrics, never as performance claims.
What stability and storage factors affect Selank research material?
Stability characterisation describes how the peptide's measured attributes change over time and under defined conditions — it is a chemistry question, not a usage instruction. Peptides can undergo several degradation pathways: hydrolysis at labile bonds, oxidation of susceptible residues, aggregation, and deamidation, each of which can generate new peaks in the HPLC profile and shift net peptide content. Selank contains no cysteine, so disulfide-related instability is not a concern, but its basic residues and proline content still make controlled storage important. Lyophilised (freeze-dried) peptide is generally the most stable presentation because low water activity slows hydrolytic and oxidative reactions; Karl Fischer water-content data on the lyophilised solid therefore provides useful context for expected stability. Once reconstituted, a peptide enters solution where degradation kinetics increase and are influenced by solvent choice, pH, temperature and light exposure. Cold-chain considerations — dispatch temperature and storage recommendations — are part of the documentation trail rather than any protocol for use. A credible stability position is supported by data: comparison of HPLC purity and mass-spectral identity at time zero and after storage intervals, and monitoring for new related substances. For research procurement in Australia, the relevant questions are whether the vendor provides storage and handling guidance, whether cold-chain integrity is maintained during dispatch, and whether stability-indicating analytical methods underpin any shelf-life statement. Stability data should always be presented as measured analytical change under stated conditions.
What documentation should accompany research Selank, and how do you read a COA?
The certificate of analysis (COA) is the central document tying a specific batch to its analytical results, and reading it critically is the most practical skill for a research buyer. A well-constructed Selank COA identifies the product name and sequence, a unique batch or lot number, the manufacture and/or analysis date, and each test performed with its method, result and acceptance criterion. Expect at minimum: an identity section (ESI-MS intact mass, ideally with MS/MS sequence confirmation), a purity section (RP-HPLC area percent with the chromatogram and stated method), and content/counterion/water data where provided (net peptide content, residual TFA, Karl Fischer). Additional sections may cover appearance, and — for applications requiring it — endotoxin or sterility testing. Traceability is essential: the batch number on the vial must match the COA, and the analytical results must be attributable to that lot rather than a generic representative profile. When comparing two suppliers of the same peptide, the more transparent COA is the one that states methods and acceptance criteria explicitly, shows the actual chromatogram and mass spectrum rather than a bare percentage, and links every figure to a dated, numbered batch. Lot-release testing and defined acceptance criteria demonstrate that material is evaluated against a specification before it is released. For Australian laboratories, this documentation framework — identity, purity, content, stability and traceability — is the objective basis for procurement decisions. None of this documentation makes or implies any claim about biological activity; it certifies chemical identity and quality for research use only.
Order Selank with documentation
If this guide helped you evaluate Selank for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Selank card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Is Selank sold as a research chemical in Australia?
Material described here is supplied strictly for laboratory research use only and is not for human or veterinary use. This article addresses only the analytical chemistry — identity, purity, stability and documentation — that lets researchers evaluate the quality of a peptide labelled Selank. It makes no claims about biological effects.
What analytical tests confirm that a peptide is genuinely Selank?
Identity is confirmed by ESI mass spectrometry comparing the observed molecular mass to the theoretical mass of the heptapeptide sequence, ideally supported by tandem MS/MS fragment-ion sequence mapping. Purity is measured separately by reversed-phase HPLC. A complete COA should present both identity and purity data with methods stated.
What purity level is typical on a Selank certificate of analysis?
Research-grade synthetic peptides are commonly documented at ≥95% or ≥98% HPLC area purity, but the meaningful detail is the stated acceptance criterion, the chromatogram and supporting net peptide content data. A high area-purity figure alone does not indicate the mass fraction of actual peptide present.
How should reconstituted Selank stability be assessed?
Stability is assessed analytically by comparing HPLC purity and mass-spectral identity at time zero and after defined storage intervals under stated temperature, solvent and light conditions, watching for new related substances. This is a chemistry measurement of degradation, not a usage recommendation.
Why does net peptide content differ from HPLC purity?
HPLC purity reports the relative peak area of the main compound, while net peptide content reflects the actual mass fraction of peptide after correcting for water (Karl Fischer) and counterion (residual TFA) mass. Both values, plus water and counterion data, give a fuller picture of the material.
References
- DOI:10.1016/s0924-9338(12)75281-1 — P-1114 - Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic selank — European Psychiatry — 2012
- DOI:10.1017/s1035077200004764 — Buy Australian: A local family preservation success — Children Australia — 1996
- DOI:10.1080/08111140601035267 — Fly Buy Cities: Some Planning Aspects of Airport Privatisation in Australia — Urban Policy and Research — 2006
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
